ASML vs. Intel: Which AI Chip Stock Is a Better Buy in 2026?

ASML raised its 2026 sales outlook to €43 billion-€45 billion from €34 billion-€39 billion in January after reporting Q2 sales of €9.3 billion and a 54% gross margin, supported by AI-driven EUV demand and multiyear customer orders. The company generated roughly $37.5 billion of FY2025 revenue, $11.0 billion of net income, and $12.2 billion of free cash flow, while its shares are up about 60% in 2026. Intel's Q2 revenue grew 25% and gross margin improved to 40.4% from 27.5%, but its foundry unit lost $2.1 billion and FY2025 free cash flow was negative $4.9 billion, leaving its turnaround dependent on execution.

Analysis

ASML’s key investment question is no longer demand visibility but duration and valuation: multi-year leading-edge fab buildouts convert into high-margin service, upgrade, and installed-base revenue after tool delivery. The more non-obvious beneficiary of sustained EUV intensity is TSM, which can monetize scarce leading-edge capacity; however, ASML captures industry capex regardless of whether NVIDIA-led demand ultimately accrues to TSM, Samsung, or Intel. The principal near-term risk is order timing: customers can defer acceptance and revenue recognition even when long-term capacity plans remain intact, creating volatility around quarterly bookings without impairing the structural thesis.

Intel’s equity now embeds a sharp improvement in both manufacturing execution and external-foundry customer wins. Gross-margin recovery can support the client/data-center earnings base over the next 1-3 quarters, but foundry losses mean incremental revenue is not necessarily incrementally valuable until utilization rises materially; a subsidized capacity build with insufficient anchor customers would prolong negative free cash flow and require further financial engineering. Government alignment lowers domestic-fab financing risk but can constrain strategic flexibility and raises the probability that capital allocation serves policy objectives rather than minority-shareholder returns.

Consensus framing of ASML as the "safer" AI expression misses that its multiple leaves little room for a cyclical digestion phase in leading-edge capex. Conversely, the market may be underpricing Intel’s option value only if it can disclose credible, economically attractive external volume commitments; vague design-win announcements are insufficient because wafer pricing, utilization, and yield determine whether foundry revenue reduces losses. The clean relative expression is quality versus execution risk, not a directional semiconductor-beta bet.

Key Decisions for Investors

• Maintain a 6-12 month long ASML / short INTC pair, sized beta-neutral: ASML has monopoly-like pricing and higher incremental returns, while INTC requires sustained yield, utilization, and customer-win proof. Take profit if the relative spread widens 15-20%; stop/reassess if ASML bookings weaken for two consecutive quarters or Intel foundry losses narrow materially alongside named high-volume customer commitments.
• Do not chase ASML after a sharp rerating; add only on a post-results pullback driven by delivery timing rather than a reduction in 2027 leading-edge capacity plans. A 10-15% drawdown with intact order visibility offers better asymmetry than buying current momentum.
• For Intel, treat external-foundry disclosures as an event-driven watch item rather than a core long. Upgrade only after evidence of rising utilization and a path to foundry break-even within 12-18 months; absent this, use rallies into earnings or customer-win headlines to fund the ASML relative long.
• Monitor TSM monthly revenue and leading-edge capex commentary as the fastest read-through for ASML tool demand. A simultaneous slowdown in TSM capex intent and NVIDIA supply-chain demand would be the principal 1-3 month catalyst to reduce ASML exposure.